企業概要
ETHZilla Corporation is a biotechnology firm that simultaneously operates as a technology company dedicated to developing Ethereum-based infrastructure for the tokenization of real-world assets. Within the healthcare sector, specifically the biotechnology industry, the company focuses on creating platforms that convert illiquid, institutional-grade assets into blockchain-based financial instruments utilizing Ethereum Layer 2 solutions. The company's current market capitalization stands at $68.63M, while its trailing twelve-month revenue is recorded at $4.11M. Although specific employee count data is unavailable, the disparity between a market cap of $68.63M and annual revenues of $4.11M indicates that the company operates on a small scale relative to its enterprise value, suggesting it is in a high-growth or early-stage development phase where market valuation often exceeds current revenue generation capabilities due to anticipated future scalability in the asset tokenization space.
財務健全性
ETHZilla Corporation reported annual revenues of $4.11M for the trailing twelve months, yet this figure is overshadowed by a net income loss of $-224,528,976 and an EBITDA of $-226,656,496. The substantial gap between the modest revenue of $4.11M and the massive net loss reveals a highly leveraged cost structure where operating expenses and interest costs significantly exceed income generation. The company generated a free cash flow of $-441,101,376, indicating a severe cash burn rate that currently limits its financial flexibility and necessitates external financing to sustain operations. Despite a gross margin of 100.0%, which suggests no direct costs of goods sold against revenue, the operating margin is a negative 5364.6% and the profit margin is 0.0%, highlighting that overhead and administrative costs are disproportionately high relative to sales. ETHZilla holds $53.31M in cash against $546.76M in total debt, resulting in a debt-to-equity ratio of 122.83, which characterizes the balance sheet as highly leveraged rather than conservative. The current ratio of 10.07 indicates a strong ability to meet short-term obligations with liquid assets, yet this liquidity must be weighed against the overwhelming total debt load. Furthermore, the return on equity is -96.5% and the return on assets is -27.8%, metrics that demonstrate management is currently destroying shareholder value and failing to generate returns on the capital deployed by investors.
バリュエーション評価
Trailing P/E and forward P/E ratios are not applicable for ETHZilla Corporation due to the company's significant net losses, implying that traditional earnings-based valuation methods cannot be applied to assess its current trajectory. The price-to-book ratio is 0.13, indicating that the market is valuing the company at a fraction of its book value, which typically suggests either deep undervaluation or fundamental concerns regarding the quality of assets held by the firm. Alternative valuation metrics such as the price-to-sales ratio of 16.70 and an EV/EBITDA of -2.52 provide a different perspective, suggesting the market is pricing the company based on its revenue potential and growth prospects rather than current profitability. ETHZilla shares have traded within a 52-week range between a high of $174.60 and a low of $2.99, meaning the current price sits significantly below the 52-week high, reflecting the volatility often seen in small-cap biotechnology firms. The stock exhibits a beta of 1.14, which means its price volatility is 14% higher than the broader market, indicating that the stock is more sensitive to market fluctuations than large-cap indices.
Growth & Income
Revenue growth year-over-year and earnings growth year-over-year figures are not available, preventing a direct comparison of how earnings are growing relative to revenue expansion. As the company does not pay dividends, the dividend yield is not applicable and the payout ratio is 0.0%, meaning the firm reinvests all available earnings and cash reserves back into research, development, and infrastructure rather than distributing income to shareholders. Consequently, the overall growth and income profile is defined entirely by capital appreciation potential rather than dividend income or current earnings expansion.